FDA and Off-Label Communication – Getting Closer to Truth
Drug & Device Law
NOVEMBER 9, 2023
IMS Health Inc. , 357 (2002); United States v. First, such communications may now be directed to any health care provider – not just health insurers seeking to determine whether an off-label use should be covered, as was previously the case. E.g. , Sorrell v. 552 (2011); Thompson v. Caronia , 703 F.3d FDA , 119 F.
64 
Let's personalize your content